Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study ; volume:9 ; number:5 ; day:17 ; month:8 ; year:2018 ; pages:2133-2141 ; date:10.2018
Diabetes therapy ; 9, Heft 5 (17.8.2018), 2133-2141, 10.2018
- Creator
-
Jermendy, György
- Contributor
-
Kiss, Zoltán
Rokszin, György
Abonyi-Tóth, Zsolt
Wittmann, István
Kempler, Péter
SpringerLink (Online service)
- DOI
-
10.1007/s13300-018-0483-4
- URN
-
urn:nbn:de:101:1-2018111113562027296509
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jermendy, György
- Kiss, Zoltán
- Rokszin, György
- Abonyi-Tóth, Zsolt
- Wittmann, István
- Kempler, Péter
- SpringerLink (Online service)
Other Objects (12)
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage